van Dalen E C, Leerink J M, Kremer L C M, Feijen E A M
Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS, Utrecht, The Netherlands.
Heart Center, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Curr Oncol Rep. 2023 Apr;25(4):353-367. doi: 10.1007/s11912-023-01368-7. Epub 2023 Feb 14.
Cancer patients are at risk for treatment-related myocardial dysfunction and heart failure during or after treatment. Risk prediction models have the potential to play an important role in identifying patients at high or low risk in order to take appropriate measures. Here, we review their current role.
More and more risk prediction models are currently being developed. Unfortunately, they vary widely in their ability to identify patients and survivors at risk for myocardial dysfunction or heart failure, from very poor to strong. Part of this variation might be explained by methodological limitations of the models, but due to a lack of reporting it is not possible to completely assess this. There lies great potential in the improvement of the quality and the use of risk prediction models to inform patients and clinicians on the absolute risk of cardiac events in order to guide care.
癌症患者在治疗期间或治疗后有发生与治疗相关的心肌功能障碍和心力衰竭的风险。风险预测模型有可能在识别高风险或低风险患者以便采取适当措施方面发挥重要作用。在此,我们综述它们目前的作用。
目前正在开发越来越多的风险预测模型。不幸的是,它们在识别有心肌功能障碍或心力衰竭风险的患者及幸存者方面的能力差异很大,从非常差到很强。这种差异部分可能由模型的方法学局限性来解释,但由于缺乏报告,无法完全评估这一点。在提高风险预测模型的质量和应用方面有很大潜力,以便告知患者和临床医生心脏事件的绝对风险,从而指导治疗。